Analysts Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) PT at $42.60

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has been given a consensus recommendation of “Moderate Buy” by the five research firms that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $42.60.

A number of analysts have recently weighed in on COLL shares. Piper Sandler reissued a “neutral” rating and set a $37.00 price objective (down previously from $39.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 31st. Truist Financial boosted their price objective on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, HC Wainwright raised their target price on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL opened at $37.56 on Friday. Collegium Pharmaceutical has a one year low of $20.95 and a one year high of $42.29. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.11 and a quick ratio of 1.04. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of 15.65 and a beta of 0.94. The company’s fifty day moving average price is $37.28 and its 200-day moving average price is $35.52.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.22. The business had revenue of $145.28 million for the quarter, compared to analysts’ expectations of $143.94 million. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The business’s quarterly revenue was up 7.2% on a year-over-year basis. During the same period last year, the business earned $1.13 earnings per share. On average, equities research analysts anticipate that Collegium Pharmaceutical will post 5.82 earnings per share for the current fiscal year.

Insider Transactions at Collegium Pharmaceutical

In other news, EVP Thomas B. Smith sold 9,593 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the sale, the executive vice president now directly owns 53,816 shares of the company’s stock, valued at $1,970,741.92. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, EVP Thomas B. Smith sold 9,593 shares of the firm’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the transaction, the executive vice president now directly owns 53,816 shares in the company, valued at $1,970,741.92. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the transaction, the executive vice president now directly owns 120,161 shares of the company’s stock, valued at approximately $4,602,166.30. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 3.98% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Caxton Associates LP purchased a new stake in shares of Collegium Pharmaceutical during the 1st quarter valued at about $1,730,000. Foundry Partners LLC bought a new position in Collegium Pharmaceutical in the second quarter valued at about $492,000. LSV Asset Management lifted its holdings in Collegium Pharmaceutical by 188.7% in the first quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock valued at $14,773,000 after acquiring an additional 248,751 shares during the period. O Shaughnessy Asset Management LLC boosted its position in Collegium Pharmaceutical by 159.3% in the first quarter. O Shaughnessy Asset Management LLC now owns 45,735 shares of the specialty pharmaceutical company’s stock worth $1,775,000 after purchasing an additional 28,100 shares during the last quarter. Finally, Avidity Partners Management LP boosted its holdings in shares of Collegium Pharmaceutical by 3.2% in the fourth quarter. Avidity Partners Management LP now owns 361,363 shares of the specialty pharmaceutical company’s stock worth $11,123,000 after buying an additional 11,163 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.